FORM PTO-1390 U.S. DEPAR (REV 12-29-99)	TMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER		
TRANSMITTAL LETTER TO THE UNITED STATES 2477USOP				
	ED OFFICE (DO/EO/US)	US APPLICATION NO (If known, see 37 CFR 15)		
•	NG UNDER 35 U.S.C. 371	09/485640		
INTERNATIONAL APPLICATION NO. PCT/JP98/03692	INTERNATIONAL FILING DATE August 20, 1998	PRIORITY DATE FAMED August 21, 1997		
TITLE OF INVENTION Anti-Inflar	nmatory Agent	(C)		
APPLICANT(S) FOR DO/EO/US	(A at al.	FEB 1 1 2000		
H. ODA	es Designated/Elected Office (DO/EO/US) the foll	owing its file and other information:		
	as concerning a filing under 35 U.S.C. 371.	TRADEMAN		
	NT submission of items concerning a filing under	r 35 U.S.C. 371		
	nal examination procedures (35 U.S.C. 371(f)) at a			
examination until the expiration of A proper Demand for International	the applicable time limit set in 35 U.S.C. 371(b) a Preliminary Examination was made by the 19th m	and PCT Articles 22 and 39(1).		
	dication as filed (35 U.S.C. 371(c)(2)) *			
_	(required only if not transmitted by the Inter	mational Bureau).		
	y the International Bureau.	· · · · · · · · · · · · · · · · · · ·		
· —	application was filed in the United States Rec			
I	al Application into English (35 U.S.C. 371(c)			
	ne International Application under PCT Artic			
I —	h (required only if not transmitted by the Inte	ernational Bureau).		
b. have been transmitted by the International Bureau.				
c. have not been made; however, the time limit for making such amendments has NOT expired.				
d. have not been made and will not be made.				
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).				
9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).				
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).				
Items 11. to 16. below concern docume	ent(s) or information included:			
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.				
12. X An assignment document for re	cording. A separate cover sheet in compliance	ce with 37 CFR 3.28 and 3.31 is included.		
13. X A FIRST preliminary amendme	nt.			
A SECOND or SUBSEQUENT preliminary amendment.				
14. A substitute specification.				
15. A change of power of attorney and/or address letter.				
16. Other items or information:				
	•			
	Express mail label #: EJ9	218098631US		
	·			
	* This includes specification Claims 1-12.	on 31 total pages, including		

	09/4	85640	PCT/JP98/03692		2477US0)P
Ī		owing fees are submitted			CALCULATIONS	PTO USE ONLY
		AL FEE (37 CFR 1.492)				
	Neither interna	ntional preliminary exami	nation fee (37 CFR 1.482)			
			445(a)(2)) paid to USPTO	\$970.00		
			pared by the EPO or JPO · · · · ·			
	USPTO but In	ternational Search Repor	· FF	\$840.00		
	international s	earch fee (37 CFR 1.445	· · · · · -	\$690 . 00		
	but all claims	did not satisfy provisions	fee paid to USPTO (37 CFR 1.48 of PCT Article 33(1)-(4)	\$670 . 00		
			fee paid to USPTO (37 CFR 1.48 CT Article 33(1)-(4)	2) \$96.00		
		ENTER APPRO	PRIATE BASIC FEE AM	IOUNT =	\$ 840.00	
		.00 for furnishing the oat earliest claimed priority of	th or declaration later than 20 late (37 CFR 1.492(e)).	30	\$	
	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		T
	Total claims	12 - 20 =	- 0	X \$18.00	\$ 0.00	
	Independent claims	3 - 3 =		X \$78.00	\$ 0.00	
aji s Nga	MULTIPLE DEPE	ENDENT CLAIM(S) (if app		+ \$260.00	\$ 0.00	
100		TOTAL	L OF ABOVE CALCULAT	TIONS =	\$ 840.00	
1 1 1 1 1	Reduction of 1/2 must also by filed	for filing by small entity, l (Note 37 CFR 1.9, 1.27,	if applicable. A Small Entity State, 1.28).	tement	\$	
			SUBT	TOTAL =	\$ 840.00	
	Processing fee of	\$130.00 for furnishing the	ne English translation later than	20 30 +	\$	
'n,	months from the earliest claimed priority date (37 CFR 1.492(f)). + TOTAL NATIONAL FEE = \$ 840.00					
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
	TOTAL FEES ENCLOSED = \$ 880.00					
					Amount to be	\$
					refunded: charged:	\$
			· · · · · · · · · · · · · · · · · · ·		Chargeu:	I
	a. A check in the amount of \$ to cover the above fees is enclosed.					
	b. X Please charge my Deposit Account No. 500799 in the amount of \$ 880.00 to cover the above fees. A duplicate copy of this sheet is enclosed.					
	c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No A duplicate copy of this sheet is enclosed.					
•	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
	SEND ALL CORRE	SPONDENCE TO:		N/	M h // _	_
	Miriam	Sohn (Reg. No. 35,368	3)	SIGNAT	TIRE:	
	Takeda	a Pharmaceuticals Ame	erica, Inc. Patent Office		ilippe Y. Riesen	
		efferson Davis Highway				
		08, Arlington VA 22202 : (703) 416-5160	2, USA	NAME 35	,657	
	Fax: (7	03) 416-5163				
	E-mail:	dmsohn@aol.com			RATION NUMBER ate: February 7, 200	00
				De	i Obliadiy 1, 200	

09/485640
Attorney Docket No. 2477US0P
416 Rec'd PCT/PTO 1 1 FEB 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

H. ODAKA et al.

Serial No.

Attn: Box PCT

Filed on

Title

Anti-Inflammatory Agent

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Preliminary to examination please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 1, line 30, delete "deivative" and substitute therefor -- derivative--

Page 2, line 13, delete "stimulation was" and substitute therefor --stimulation is--

Page 2, line 30, delete "increased" and substitute therefor --increases--

Page 22, line 24, delete "wells" and substitute therefor --well--

Page 22, line 28, delete "wells" and substitute therefor --well--

Page 22, line 33, delete "wells" and substitute therefor --well--

Page 22, line 35, delete "wells" and substitute therefor --well--

Page 23, line 2, delete "wells" and substitute therefor --well--

Page 23, line 8, delete "wells" and substitute therefor --well--

Page 23, line 12, delete "wells" and substitute therefor --well--

In the Claims:

Claim 12, page 30, line 23, delete "Use of" and substitute therefor -- A method of using--

<u>REMARKS</u>

The above amendments correct typographical and clerical errors and do not constitute new matter. Entry of the above amendments prior to examination is respectfully requested. Early action on the merits is earnestly solicited.

Respectfully submitted,

Philippe Y. Riesen

Registration No. 35,657 Attorney for Applicants

c/o Takeda Chemical Industries, Ltd.

17-85 Jusohonmachi 2-chome

Yodogawa-ku, Osaka, Japan 532-8686 Phone #: 81-6-6300-6124

Fax # : 81-6-6300-6601

Date: February 7, 2000

● 09/485640 416 Rec'd PCT/PTO 1 1 FEB 2000

DESCRIPTION ANTI-INFLAMMATORY AGENT

TECHNICAL FIELD

The present invention relates to an anti-inflammatory agent which is useful as an agent for prophylaxis and treatment of a TNF(Tumor Necrosis Factor)- α mediated inflammatory disease.

10 BACKGROUND ART

Regarding a relationship between TNF- α and a thiazolidine derivative, the following references 1) to 4) are known.

- 1) JP-A H7(1995)-285864 describes that a thiazolidine derivative inhibits production and response reaction of TNF.
- 2) Saishin-Igaku, Vol. 52, No.6, pp.95~102 (1997) describes that a thiazolidine derivative reduces expression of TNF- α and improves insulin-resistance caused by TNF- α .
- 3) Endocrinology, Vol. 134, No. 1, pp.264-270 (1994) describes that the overexpression of mRNA for TNF- α and both of its receptors are at least partly normalized by treatment of the diabetic animals with the insulinsensitizing agent pioglitazone.
- 4) Endocrinology, Vol. 136, No. 4, pp.1474-1481 (1995) describes that insulin-sensitizing agents exert their antidiabetic activities by antagonizing the inhibitory effects of TNF- α .

While, regarding a relationship between an inflammatory disease and a thiazolidine deivative, the following references 5) and 6) are known.

- 5) WO 96/34943 describes a method for treating a cytokine mediated autoimmune, inflammatory or atherosclerotic disorder with a human 12-lipoxygenase inhibitor. The
- human 12-lipoxygenase inhibitor is exemplified by pioglitazone, namely 5-[4-[2-(5-ethyl-2-

15

20

25

30

35

pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione.

6) The Journal of Biological Chemistry, Vol.271, No.23, pp.13515-13522 (1996) describes that a thiazolidinedione related compound such as 1-(3-allyl-4-oxothiazolidine-2-yliden)-4-methylthiosemicarbazone exhibits antiarthritic activity.

However, none of the above references describes that a thiazolidine derivative is useful as an agent for prophylaxis and treatment of a TNF- α mediated inflammatory disease.

An inflammatory reaction includes various acute and

chronic reactions which occur when stimulation was added to the living body. Such reactions include unfavorable reactions which cause destruction of the living tissues as well as favorable reactions to the living body with the purpose of excluding the alien substance. So far, inflammatory diseases are treated with steroid or a nonsteroidal anti-inflammatory agent, an immunosuppressive agent, and the like. However, such agents have problems that they inhibit favorable reactions as well as unfavorable reactions at the time of inflammation. Therefore, agents which inhibit only unfavorable reactions to the living body are desired.

It is thought that various cytokines are produced to regulate inflammation reactions at the time of inflammation. TNF- α which is one of such cytokines is thought to play an important role in expansion and delay of inflammation. For instance, it is thought that production of TNF- α increased to cause destruction of articular tissues in rheumatoid arthritis which belongs to an inflammatory disease.

Based on the above situations, agents which specifically inhibit TNF- α mediated inflammation reactions are expected to be an anti-inflammatory agent with reduced side effects, therefore development of such

15

20

25

30

35

agents are desired.

DISCLOSURE OF INVENTION

The present invention relates to

(1) An anti-inflammatory agent which affects by way of a TNF- α inhibitory action and comprises a compound of the formula:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{0} \xrightarrow{R^{1}} E \xrightarrow{L} A - CH_{0} \xrightarrow{L} C = 0$$

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR³- where R³ represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R¹ represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R¹; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof (hereinafter referred to simply as Compound (I));

- (2) An anti-inflammatory agent according to the above (1), wherein the heterocyclic group represented by R is a 5- to 7-membered monocyclic and heterocyclic group containing 1 to 4 hetero-atoms selected from oxygen, sulfur and nitrogen in addition to carbon as ring members or a condensed heterocyclic group;
- (3) An anti-inflammatory agent according to the above (1), wherein R represents a heterocyclic group that may be substituted;
- (4) An anti-inflammatory agent according to the above (3),

wherein the heterocyclic group is pyridyl, oxazolyl or thiazolyl;


(5) An anti-inflammatory agent according to the above (1), wherein the partial structural formula:

5

10

20

35



- (6) An anti-inflammatory agent according to the above (1), wherein X represents CH;
- (7) An anti-inflammatory agent according to the above (1), wherein R^1 represents hydrogen;
- (8) An anti-inflammatory agent according to the above (1), wherein L and M respectively represent hydrogen;
- (9) An anti-inflammatory agent according to the above (1), wherein the compound is 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione;
 (10) An anti-inflammatory agent according to the above (1),
 - wherein the compound is (R)-(+)-5-[3-[4-[2-(2-fury1)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-
 - oxazolidinedione;
 - (11) Method for treating or preventing a TNF- α mediated inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount
- of a compound as defined in the above (1) or a pharmacologically acceptable salt thereof; and
- (12) Use of a compound as defined in the above (1) or a pharmacologically acceptable salt thereof for the manufacture of an agent for prophylaxis or treatment of a 30 TNF- α mediated inflammatory disease.

Referring to the hydrocarbon group that may be substituted for R, the hydrocarbon group includes aliphatic, alicyclic, alicyclic-aliphatic, aromatic-aliphatic, and aromatic hydrocarbon groups. The number of carbon atoms constituting such hydrocarbon groups is preferably 1 to 14.

15

20

25

30

35

The aliphatic hydrocarbon group is preferably a C_{1-8} aliphatic hydrocarbon group. The aliphatic hydrocarbon group includes saturated C_{1-8} aliphatic hydrocarbon groups (e.g. alkyl groups) such as methyl, ethyl, propyl,

isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, t-pentyl, hexyl, isohexyl, heptyl, and octyl; and unsaturated C_{2-8} aliphatic hydrocarbon groups (e.g. alkenyl, alkadienyl, alkynyl, and alkadiynyl groups) such as ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-

butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl,
1-hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1heptenyl, 1-octenyl, ethynyl, 1-propynyl, 2-propynyl,
1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl,

3-pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexadiynyl, 5-hexynyl, 1-heptynyl, and 1-octynyl.

The alicyclic hydrocarbon group is preferably a C_{3-7} alicyclic hydrocarbon group. The alicyclic hydrocarbon group includes saturated C_{3-7} alicyclic hydrocarbon groups (e.g. cycloalkyl groups) such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. and unsaturated C_{5-7} alicyclic hydrocarbon groups (e.g. cycloalkenyl groups and cycloalkadienyl groups) such as 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3-cyclohexenyl, and 2,4-cycloheptadienyl.

The alicyclic-aliphatic hydrocarbon group is a group consisting of the above-described alicyclic hydrocarbon group and aliphatic hydrocarbon group (e.g. cycloalkyl-alkyl and cycloalkenyl-alkyl groups) and is preferably a C_{4-9} alicyclic-aliphatic hydrocarbon group. Specifically, the alicyclic-aliphatic hydrocarbon group includes cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3-cyclopentenylmethyl, cyclohexylmethyl, 2-

10

15

20

25

30

35

cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, cycloheptylethyl, etc.

The aromatic-aliphatic hydrocarbon group is preferably a C_{7-13} aromatic-aliphatic hydrocarbon group (e.g. aralkyl and aryl-alkenyl groups). The aromatic-aliphatic hydrocarbon group includes C_{7-9} phenylalkyl such as benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and 1-phenylpropyl; C_{11-13} naphthylalkyl such as α -naphthylmethyl, α -naphthylethyl, β -naphthylmethyl, and β -naphthylethyl; C_{8-10} phenylalkenyl such as styryl and 4-phenyl-1,3-butadienyl; and C_{12-13} naphthylalkenyl such as 2-(2-naphthyl)vinyl.

The aromatic hydrocarbon group is preferably a C_{6-14} aromatic hydrocarbon group (e.g. aryl groups). The aromatic hydrocarbon group includes phenyl and naphthyl (α -naphthyl).

Referring to the formula (I), the heterocyclic group in a heterocyclic group that may be substituted for R is a 5- to 7-membered monocyclic and heterocyclic group containing 1 to 4 hetero-atoms selected from oxygen, sulfur, and nitrogen in addition to carbon as ring members or a condensed heterocyclic group. The condensed heterocyclic group may for example be one consisting of such a 5- to 7-membered monocyclic and heterocyclic group and a 6-membered ring containing 1 or 2 nitrogen atoms, a benzene ring, or a 5-membered ring containing one sulfur atom.

Specifically the heterocyclic group includes 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyridinyl, 5-pyrimidinyl, 6-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, isothiazolyl, isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1,2,4-oxadiazol-5-yl, 1,2,4-triazol-3-yl, 1,2,3-triazol-4-yl, tetrazol-5-yl, benzimidazol-2-yl,

10

15

20

25

30

35

indol-3-yl, 1H-indazol-3-yl, 1H-pyrrolo[2,3-b]pyrazin-2-yl, 1H-pyrrolo[2,3-b]pyridin-6-yl, 1H-imidazo[4,5-b]pyridin-2-yl, 1H-imidazo[4,5-c]pyridin-2-yl, 1H-imidazo[4,5-b]pyrazin-2-yl, benzopyranyl and 3,4-dihydrobenzopyran-2-yl. The preferred heterocyclic group is pyridyl, oxazolyl, or thiazolyl.

Referring to the formula (I), the hydrocarbon group and heterocyclic group for R may respectively have 1 to 5, preferably 1 to 3 substituents at substitutable positions.

Such substituents include for example aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, aryl groups, aromatic heterocyclic groups, non-aromatic heterocyclic groups, halogen, nitro, amino group that may be substituted, acyl groups that may be substituted, hydroxy group that may be substituted, thiol that may be

The aliphatic hydrocarbon group includes straight-chain or branched aliphatic hydrocarbon groups having 1 to 15 carbon atoms, such as alkyl groups, alkenyl groups, and alkynyl groups.

substituted, and carboxyl group that may be esterified.

The preferred alkyl group is a C_{1-10} alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, t-pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, hexyl, pentyl, octyl, nonyl, and decyl.

The preferred alkenyl group is a C₂₋₁₀ alkenyl group, such as vinyl, allyl, isopropenyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, and 5-hexenyl.

The preferred alkynyl group is a C₂₋₁₀ alkynyl group, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl,

and 5-hexynyl.

5

15

30

35

The alicyclic hydrocarbon group includes saturated and unsaturated alicyclic hydrocarbon groups having 3 to 12 carbon atoms, such as cycloalkyl groups, cycloalkenyl groups, and cycloalkadienyl groups.

The preferred cycloalkyl group is a C_{3-10} cycloalkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl, cyclohexyl,

bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl,

bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl,
bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, and
bicyclo[4.3.1]decyl.

The preferred cycloalkenyl group is a C_{3-10} cycloalkenyl group, such as 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl, and 3-cyclohexen-1-yl.

The preferred cycloalkadienyl group is a C_{4-10} cycloalkadienyl group, such as 2,4-cyclopentadien-1-yl, 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl.

The term "aryl group" means a monocyclic or condensed polycyclic aromatic hydrocarbon group. As preferred examples, C₆₋₁₄ aryl groups such as phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl can be mentioned.

Particularly preferred are phenyl, 1-naphthyl, and 2-naphthyl.

The preferred aromatic heterocyclic group includes 5to 7-membered monocyclic aromatic heterocyclic groups
containing 1 to 4 hetero-atoms selected from oxygen, sulfur,
and nitrogen in addition to carbon as ring members, such
as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl,
thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl,
furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,
1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,
tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,
and triazinyl; and bicyclic or tricyclic condensed aromatic

25

30

35

heterocyclic groups containing 1 to 5 hetero-atoms selected from oxygen, sulfur, and nitrogen in addition to carbon as ring members, such as benzofuranyl, isobenzofuranyl, benzo[b]thienyl, indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, 1,2-benzisoxazolyl, 5 benzothiazolyl, 1,2-benzisothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl, purinyl, pteridinyl, carbazolyl, lpha-carbolinyl, eta-carbolinyl, γ 10 -carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, phenanthridinyl, phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl, 15 1,2,4-triazolo[4,3-a]pyridyl, and 1,2,4-triazolo[4,3b]pyridazinyl.

The preferred non-aromatic heterocyclic group includes oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolidino, piperidino, and morpholino.

The halogen includes fluorine, chlorine, bromine, and iodine, and is preferably fluorine or chlorine.

The amino group that may be substituted includes amino $(-NH_2)$ that may be mono- or di-substituted by, for example, C_{1-10} alkyl groups, C_{3-10} cycloalkyl groups, C_{2-10} alkenyl groups, C_{3-10} cycloalkenyl groups, C_{1-13} acyl groups (e.g. C_{2-10} alkanoyl groups, C_{7-13} arylcarbonyl groups), or C_{6-12} aryl groups. As examples of the substituted amino group, there can be mentioned methylamino, dimethylamino, ethylamino, diethylamino, dibutylamino, diallylamino, cyclohexylamino, acetylamino, propionylamino, benzoylamino, phenylamino, and N-methyl-N-phenylamino.

The acyl group in the acyl groups that may be substituted includes C_{1-13} acyl groups. For example, formyl

20

25

35

and groups formed between carbonyl and C₁₋₁₀ alkyl groups, C₃₋₁₀ cycloalkyl groups, C₂₋₁₀ alkenyl groups, C₃₋₁₀ cycloalkenyl groups, C₆₋₁₂ aryl groups, or aromatic heterocyclic groups (e.g. thienyl, furyl, pyridyl). The preferred acyl group includes acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2-cyclohexenecarbonyl, benzoyl, and nicotinoyl. The substitutent in the substituted acyl groups includes C₁₋₃ alkyl, C₁₋₃ alkoxy groups, halogen (e.g. chlorine, fluorine, bromine, etc.), nitro, hydroxy, and amino.

Referring to the hydroxy group that may be substituted, the substituted hydroxy includes alkoxy, alkenyloxy, aralkyloxy, acyloxy, and aryloxy groups.

The preferred alkoxy group includes C_{1-10} alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, t-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, heptyloxy, nonyloxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.

The preferred alkenyloxy group includes C_{2-10} alkenyloxy groups, such as allyloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2-cyclopentenylmethoxy, and 2-cyclohexenylmethoxy.

The preferred aralkyloxy group includes C_{7-10} aralkyloxy groups, such as phenyl- C_{1-4} alkyloxy (e.g. benzyloxy, phenethyloxy, etc.).

The preferred acyloxy group includes C_{2-13} acyloxy groups, more preferably C_{2-4} alkanoyloxy (e.g. acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, etc.).

The preferred aryloxy group includes C_{6-14} aryloxy groups, such as phenoxy, and naphthyloxy. This aryloxy group may have 1 or 2 substituents such as halogen (e.g. chlorine, fluorine, bromine, etc.). The substituted aryloxy group includes 4-chlorophenoxy.

10

15

20

25

30

35

Referring to the thiol group that may be substituted, the substituted thiol group includes alkylthio, cycloalkylthio, aralkylthio, and acylthio groups.

The preferred alkylthio group includes C_{1-10} alkylthio groups, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, t-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, heptylthio, and nonylthio. The preferred cycloalkylthio group includes C_{3-10} cycloalkylthio groups such as cyclobutylthio, cyclopentylthio, and cyclohexylthio.

The preferred aralkylthio group includes C_{7-10} aralkylthio groups, such as phenyl- C_{1-4} alkylthio (e.g. benzylthio, phenethylthio, etc.).

The acylthic group is preferably a C_{2-13} acylthic group, more preferably a C_{2-4} alkanoylthic group (e.g. acetylthic, propionylthic, butyrylthic, isobutyrylthic, etc.).

The carboxyl group that may be esterified includes alkoxycarbonyl, aralkyloxycarbonyl, and aryloxycarbonyl groups.

The preferred alkoxycarbonyl group includes C_{2-5} alkoxycarbonyl groups, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and butoxycarbonyl.

The preferred aralkyloxycarbonyl group includes $C_{8\text{--}10}$ aralkyloxycarbonyl groups, such as benzyloxycarbonyl.

The preferred aryloxycarbonyl group includes C_{7-15} aryloxycarbonyl groups, such as phenoxycarbonyl, and ptolyloxycarbonyl.

The preferred substituent on the hydrocarbon or heterocyclic group for R includes C_{1-10} alkyl groups, aromatic heterocyclic groups, and C_{6-14} aryl groups. Particularly preferred is C_{1-3} alkyl, furyl, thienyl, phenyl, or naphthyl.

Referring to the formula (I), when the substituent on the hydrocarbon or heterocyclic group for R is an alicyclic hydrocarbon group, an aryl group, an aromatic heterocyclic

15

20

25

30

35

group, or a non-aromatic heterocyclic group, this substituent may be further substituted by one or more, preferably 1 to 3 suitable substituents. As such substituents, there can be mentioned C_{1-6} alkyl groups, C_{2-6} alkenyl groups, C2-6 alkynyl groups, C3-7 cycloalkyl groups, C₆₋₁₄ aryl groups (e.g. phenyl, naphthyl, etc.), aromatic heterocyclic groups (e.g. thienyl, furyl, pyridyl, oxazolyl, thiazolyl, etc.), non-aromatic heterocyclic groups (e.g. tetrahydrofuryl, morpholino, thiomorpholino, piperidino, pyrrolidino, piperazino, etc.), C7-9 aralkyl groups, amino, N-mono(C_{1-4})alkylamino groups, N,N-di(C_{1-4}) a) alkylamino groups, C2-8 acylamino groups (e.g. acetylamino, propionylamino, benzoylamino, etc.), amidino, C2-8 acyl groups (e.g. C_{2-8} alkanoyl groups, etc.), carbamoyl, N $mono(C_{1-4})$ alkylcarbamoyl groups, N,N-di(C_{1-4}) $_4$)alkylcarbamoyl groups, sulfamoyl, N-mono(C_{1-} a)alkylsulfamoyl groups, N, N-di(C1-4)alkylsulfamoyl groups, carboxyl, C2-8 alkoxycarbonyl groups, hydroxy, C1-4 alkoxy groups, C2-5 alkenyloxy groups, C3-7 cycloalkyloxy groups, C_{7-9} aralkyloxy groups, C_{6-14} aryloxy groups (e.g. phenyloxy, naphthyloxy, etc.), mercapto, C_{1-4} alkylthio groups, C_{7-9} aralkylthio groups, C_{6-14} arylthio groups (e.g. phenylthio, naphthylthio, etc.), sulfo, cyano, azido, nitro, nitroso, and halogen (e.g. fluorine, chlorine, bromine, iodine).

In the formula (I), R is preferably a heterocyclic group that may be substituted. More preferably, R is pyridyl, oxazolyl, or thiazolyl group, which may have 1 to 3 substituents selected from C_{1-3} alkyl, furyl, thienyl, phenyl, and naphthyl.

Referring to the formula (I), Y represents -CO-, -CH(OH) - or -NR3-. Y is preferably -CH(OH) - or -NR3- and more preferably -CH(OH)-. Referring to an alkyl group that may be substituted for R3, the alkyl group includes C1-4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and t-butyl. The substituent

includes halogen (e.g. fluorine, chlorine, bromine,

10

15

20

25

iodine), C_{1-4} alkoxy groups (e.g. methoxy, ethoxy, propoxy, butoxy, isobutoxy, sec-butoxy, t-butoxy), hydroxy, nitro, and C_{1-4} acyl groups (e.g. formyl, acetyl, propionyl, etc.).


The symbol m represents 0 or 1 and is preferably 0.

The symbol n represents 0, 1 or 2 and is preferably
0 or 1.

The symbol X represents CH or N and is preferably CH. Referring to the formula (I), the symbol A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms. This aliphatic hydrocarbon group may be straight-chain or branched and may further be saturated or unsaturated. Thus, for example, -CH2-, - $CH(CH_3)-$, $-(CH_2)_2-$, $-CH(C_2H_5)-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, -(CH₂)₆-, -(CH₂)₇-, etc. can be mentioned for the saturated bivalent aliphatic hydrocarbon group, while -CH=CH-, - $C(CH_2) = CH_1$, $-CH_2 = CH_2 - CH$ CH=CH-CH,-, etc. can be mentioned for the unsaturated bivalent aliphatic hydrocarbon group. The symbol A preferably represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 4 carbon atoms, which is preferably a saturated group. More preferably, A represents a chemical bond, $-CH_2$ - or $-(CH_2)_2$ -. Still more preferably, A represents a chemical bond or -(CH2)2-.

The alkyl group for R^1 includes C_{1-4} alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and t-butyl. Preferably, R^1 represents hydrogen.

Referring to the formula (I), the partial structural 30 formula:



35 wherein each symbols has the same meanings as defined above. Furthermore, ring E may optionally have 1 to 4

15

20

25

substituents at substitutable positions. Such substituents include an alkyl group, a hydroxy group that may be substituted, halogen, an acyl group that may be substituted, nitro, and an amino group that may be substituted. These substituents may be the same as the substituents mentioned for the hydrocarbon or heterocyclic group for R.

Ring E, the partial structural formula:

10 E is preferably the formula:

wherein R² represents hydrogen, an alkyl group, a hydroxy group that may be substituted, halogen, an acyl group that may be substituted, nitro, or an amino group that may be substituted.

The alkyl group, hydroxy group that may be substituted, halogen, acyl group that may be substituted, and amino group that may be substituted, for R^2 , may each be the same as the substituents mentioned for the hydrocarbon or heterocyclic group for R. Preferably, R^2 is hydrogen, hydroxy group that may be substituted, or halogen. More preferably, R^2 is hydrogen or hydroxy group that may be substituted. Particularly preferred is hydrogen or a C_{1-4} alkoxy group.

L and M respectively represent hydrogen or may be combined with each other to form a chemical bond, and preferably they are hydrogen.

Referring to the formula (I), the compound in which 30 L and M are combined with each other to form a chemical bond:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{0} = C + CH_{0} + CH_{0} = C + CH_{0} + CH_{0} = C + CH_{0} + CH_{0} + CH_{0} = C + CH_{0} + C$$

15

20

25

wherein each symbols has the same meanings as defined above, may exist as (E)- and (Z)- isomers, owing to the double bond at 5-position of the azolidinedione ring.

The compound in which L and M respectively represent bydrogen:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{0}$$


$$E - A - CH_{2} - CH_{0} = 0$$

$$NH$$

$$(I - A 2)$$

wherein each symbols has the meanings as defined above, may exist as optical isomers, i.e. (R)- and (S)-forms, with respect to the asymmetric carbon at 5-position of the azolidinedione ring. This compound includes those optically active compounds, i.e. (R)- and (S)-forms, as well as the racemic form.

The preferred compound of the formula (I) is the compound in which R represents pyridyl, oxazolyl, or thiazolyl group, optionally having 1 to 3 substituents selected from the group consisting of C_{1-3} alkyl, furyl, thienyl, phenyl, and naphthyl; Y represents -CH(OH)- or -NR³- wherein R³ is methyl; n is 0 or 1; X represents CH; A represents a chemical bond or -(CH₂)₂-; R¹ represents hydrogen; ring E, namely the partial structural formula:



30 wherein R^2 is hỳdrogen or a C_{1-4} alkoxy group; and L and M respectively represent hydrogen.

As preferred species of the compound of the formula (I), the following compounds are mentioned.

- 1) 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-
- 35 thiazolidinedione:
 - 2) 5-[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-

30

oxazolyl)ethoxy]benzyl]-2,4-thiazolidinedione;

- 3) (R)-(+)-5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione;
- 5 4) (S)-(-)-5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione;
 - 5) 5-[3-[3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propyl]-2,4-oxazolidinedione;
- 6) 5-[5-[3-methoxy-4-(5-methyl-2-phenyl-4oxazolylmethoxy)phenyl]pentyl]-2,4-oxazolidinedione;
 - 7) 5-[3-[3,5-dimethoxy-4-[2-[(E)-styry1]-4-oxazolylmethoxy]phenyl]propyl]-2,4-oxazolidinedione;
 - 8) 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-
- 2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione;
 - 9) 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione.

Hereafter, these compounds are sometimes simply referred to as compound No.1, compound No.2, and the like.

Among the above compounds, compound Nos. 1, 3, 8 and 9 are preferred, and compound Nos. 1 and 3 are particularly preferred.

25 The salt of compound (I) of the present invention is preferably a pharmacologically acceptable salt, which includes salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.

The preferred salt with an inorganic base includes alkali metal salts such as sodium salt, potassium salt, etc.; alkaline earth metal salts such as calcium salt, magnesium salt, etc.; aluminum salt, and ammonium salts.

The preferred salt with an organic base includes salts
with trimethylamine, triethylamine, pyridine, picoline,
ethanolamine, diethanolamine, triethanolamine,

dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.

The preferred salt with an inorganic acid includes salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.

The preferred salt with an organic acid includes salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.

The preferred salt with a basic amino acid includes salts with arginine, lysine, ornithine, etc. The preferred salt with an acidic amino acid includes salts with aspartic acid, glutamic acid, etc.

The most preferred of all the above-mentioned salts is hydrochloride, sodium salt or potassium salt.

Compound (I) or a salt thereof of the present invention can be produced in accordance with methods described in JP-A S55(1980)-22636 (EP-A-8203), JP-A S60(1985)-208980 (EP-A-155845), JP-A S61(1986)-286376 (EP-A-208420), JP-A S61(1986)-085372 (EP-A-177353), JP-A S61(1986)-267580 (EP-A-193256), JP-A H5(1993)-86057 (WO-A-9218501), JP-A H7(1995)-82269 (EP-A-605228), JP-A H7(1995)-101945 (EP-A-612743), EP-A-643050, EP-A-710659 (JP-A H9(1997)-194467), etc, or methods analogous thereto.

25

30

35

5

10

15

20

Compound (I) or a salt thereof of the present invention (hereinafter simply referred to as compound of the present invention) is useful as an anti-inflammatory agent which affects by way of a TNF- α inhibitory action. In addition, the toxic potential of the compound of the present invention is low. The TNF- α inhibitory action means reduction in the production amount of TNF- α in the living tissues (e.g., skeletal muscles, monocytes, macrophages, neutrophils, fibroblasts, epithelial cells, astrocytes, etc.) and reduction in the activity of TNF- α .

The anti-inflammatory agent of the present invention can be used as an agent for prophylaxis and treatment of TNF- α mediated inflammatory diseases in mammals (e.g., man, mouse, rat, rabbit, dog, cat, bovine, equine, swine, monkey, etc.). The TNF- α mediated inflammatory diseases mean inflammatory diseases which occur in the presence of TNF- α and can be treated by way of a TNF- α inhibitory action.

Examples of such inflammatory diseases include diabetic complications (e.g., retinopathy, nephropathy, neutropathy, disorders in the great arteries, etc.), rheumatoid arthritis, osteoarthritis of the spine, osteoarthritis, low back pain, gout, postoperative or traumatic inflammation, remission of swelling, neuralgia, laryngopharyngitis, cystitis, hepatitis, pneumonia, etc.

15

20

25

30

35

10

5

As the anti-inflammatory agent of the present invention, the compound of the present invention as such can be used. Usually, the anti-inflammatory agent is used in the form of a pharmaceutical composition obtained by formulating the compound of the invention with <u>per se</u> known pharmaceutically acceptable carriers.

As the pharmaceutically acceptable carrier, a variety of organic and inorganic carriers in common use as raw materials for pharmaceutical preparations are employed. The carrier is formulated in the form of the excipient, lubricant, binder, and disintegrator for a solid dosage form; and the solvent, solubilizer, suspending agent, isotonizing agent, buffering agent and local analgesic for a liquid dosage form. When necessary, pharmaceutical additives such as the preservative, antioxidant, coloring agent, sweetener, etc. can also be used.

The preferred excipient includes lactose, sucrose, D-mannitol, starch, crystalline cellulose, light silicic anhydride, etc.

The preferred lubricant includes magnesium stearate, calcium stearate, talc, colloidal silica, etc.

10

15

20

25

30

35

The preferred binder includes crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.

The preferred disintegrator includes starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethylstarch sodium, etc.

The preferred solvent includes water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, tricaprylin, etc.

The preferred solubilizer includes polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.

The preferred suspending agent includes surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate, etc. and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose, hydroxymethylcellulose, etc.

The preferred isotonizing agent includes sodium chloride, glycerin, D-mannitol, etc.

The preferred buffering agent includes buffer solutions such as phosphate, acetate, carbonate, citrate, etc.

The preferred local anesthetic includes benzyl alcohol, etc.

The preferred antiseptic includes p-hydroxybenzoic esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.

The preferred antioxidant includes salts of sulfurous acid, ascorbic acid, etc.

The above pharmaceutical composition can be manufactured by conventional methods in the pharmaceutical

10

15

20

30

preparation techniques, for example methods described in the Japanese Pharmacopoeia.

Examples of dosage forms of the pharmaceutical composition include oral dosage forms such as tablets, capsules (inclusive of soft capsules and microcapsules), powders, granules, and syrups; and non-oral dosage forms such as injections, suppositories, pellets, and drip infusions. These dosage forms can be safely administered either orally or non-orally.

The dosage of the anti-inflammatory agent of the present invention differs depending on the subject, route of administration, clinical condition, etc. For oral administration to an adult patient, for instance, the usual unit dose is about 0.1 mg/kg to about 30 mg/kg, preferably about 2 mg/kg to about 20 mg/kg, as the compound of the invention which is an active ingredient, which dose is preferably administered once to 3 times a day.

BEST MODE FOR CARRYING OUT THE INVENTION

The following examples and test examples are intended to describe the present invention in further detail and should by no means be construed as defining the scope of the invention.

Example 1

A fluidized-bed granulating and drying machine (produced by powerex, Japan) was charged with 2479.5 g of hydrochloride of Compound No.1 (2250 g in terms of Compound No.1), 13930.5 g of lactose and 540 g of carboxymethylcellulose calcium (carmellose calcium),

followed by mixing at the preheating temperature and spraying 7500 g of an aqueous solution containing 450 g of hydroxypropylcellulose to yield granules. 16820 g of the granules were processed with cutter-mill (produced by Showa Kagaku Kikai Kousakusho, Japan) to yield milled granules.

35 16530 g of the milled granules, 513 g of carmellose calcium and 57 g of magnesium stearate were mixed to yield

lubricated powders by using tumbling mixer (produced by Showa Kagaku Kikai Kousakusho, Japan). 16800 g of the lubricated powders were tabletted by using tabletting machine (produced by Kikusui Seisakusho, Japan) to yield 140000 tablets having the following formula and each containing 15 mg of Compound No. 1.

Formula per tablet (Unit: mg):

	 Hydrochloride of Compound No.1 	16.53
	2) Lactose	92.87
10	Carmellose calcium	7.2
	4) Hydroxypropylcellulose	3.0
	5) Magnesium stearate	0.4
	Total:	120.0

15 Example 2

5

In substantially the same manner as in Example 1, 140000 tablets having the following formula and each containing 30 mg of Compound No.1 were obtained. Formula per tablet (Unit: mg):

20	1) Hydrochloride of Compound No.1	33.06
	2) Lactose	76.34
	Carmellose calcium	7.2
	4) Hydroxypropylcellulose	3.0
	5) Magnesium stearate	0.4
25	Total:	120.0

Example 3

30

In substantially the same manner as in Example 2, 140000 tablets having the following formula and each containing 45 mg of Compound No.1 were obtained. Formula per tablet (Unit: mg):

	1) Hydrochloride of Compound No.1	49.59
	2) Lactose	114.51
	3) Carmellose calcium	10.8
35	4) Hydroxypropylcellulose	4.5
	5) Magnesium stearate	0.6

10

15

20

25

30

35

Total: 180.0

Test Example 1 (Reduction of plasma TNF- α level in mice) The plasma TNF- α level was determined by using KKA mice which are genetically obese, diabetic models, and a TNF- α inhibitory action of the compound of the present invention was evaluated.

Namely, eighteen male KKA^y mice (10 week old), genetically obese, diabetic models, were divided into two groups each of which consists of nine mice. A powdered commercial diet (CE-2, produced by Japan Clea) was given to one group (control group), and the above powdered diet also containing 0.001 %(w/w) of hydrochloride of Compound No. 1 was given to the other group (drug administration group) ad libitum. Mice in these groups were bred for 4 days. The average dosage of drug per mouse was 16 mg/kg body weight/day. On the fourth day, mice were sacrificed and blood was collected in tubes containing heparin.

The collected blood was centrifuged and the plasma TNF- α level was determined by the enzyme immunoassay based on the biotin-streptavidin method. Namely, 5 μ l of a solution of an anti-TNF- α antibody IgG [produced by Genzyme, USA] (100 μ g/ml) diluted with 0.05 M Tris-HCl buffer (pH 8.0) was added to each wells of a 96-well polystyrene microtiter plate [produced by Falcon, USA], followed by standing at the room temperature for 2 hours to adhere the anti-TNF- α antibody IgG to the plate. After removal of an excess antibody solution, each wells was washed with 0.1 M Tris-HCl buffer (pH 7.6) containing 0.4 M NaCl, 0.1 %(w/w) bovine serum albumin, 0.1 %(w/w) NaN₃ and 1 mM MgCl₂ (hereafter referred to as a washing buffer).

Ten μ l of plasma or standard solution of TNF- α [Serotec, Great Britain] was added to each wells, followed by standing for 2.5 hours at the room temperature. After each wells was washed with a washing buffer, 200 μ l of a solution of a biotinylated anti-TNF- α antibody IgG (35)

15

20

ng/ml) diluted with a washing buffer was added, followed by standing over night at 4 $^{\circ}$ C. After each wells was washed with a washing buffer, 20 μ l of a solution of a β -D-galactosidase-linked streptavidin [produced by Boehringer Mannheim GmbH, Germany] diluted 6000 fold with a washing buffer was added, followed by standing for one hour at the room temperature.

Then, each wells was washed with a washing buffer, and β -D-galactosidase activity of an immune complex fixed at a solid phase was assayed. Namely, 30 μ l of a substrate [60 mM of 4-methylumbelliferyl- β -D-galactoside, produced by Sigma, USA] was added to each wells to start an enzyme reaction. After the reaction was conducted at the room temperature for 4 hours, the enzyme reaction was stopped by addition of 0.13 ml of 0.1 Mglycine-NaOH buffer (pH 10.3). The fluorescence intensity of the produced 4-methylumbelliferone was determined using a fluorescence spectrometer [Cyto Fluor II, PerSeptive Biosystems, USA] at the wavelengths of 350 and 460 nm for excitation and emission, respectively.

Then, the amount of TNF- α was calculated from the obtained fluorescence intensity using a separately prepared dose-response curve.

The results are shown in Table 1.

25 Table 1. Plasma TNF- α level (pg/ml)

Control	Drug administration group
group	(Present invention)
4.97±1.75	1.52±1.08**

30 Mean \pm Standard Deviation; Significantly different from Control group (**:p<0.01)

It is apparent from Table 1 that the compound of the present invention significantly reduced plasma TNF- α level in mice.

35

Test Example 2 (Reduction of plasma TNF- α level in rats)

The plasma TNF- lpha level was determined by using Wistar fatty rats which are genetically obese, diabetic models, and a TNF- α inhibitory action of the compound of the present invention was evaluated.

Namely, hydrochloride of Compound No. 1 was orally administered to sixteen male Wistar fatty rats (16 week old), genetically obese, diabetic models, via gastric tube at a dose of 3 mg/kg body weight/day. Ten rats were sacrificed before drug administration, and the first, second, third and fourth day after drug administration, respectively. Then, blood was collected.

As the normal group, ten Wistar lean rats (16 week old) were sacrificed without drug administration and blood was collected.

The collected blood was centrifuged, and the plasma TNF- lpha level was determined in substantially the same manner as in Test Example 1.

The results are shown in Table 2. Plasma TNF- α level (pg/ml)

20			
		Days after drug	TNF - $lpha$
		administration	level (pg/ml)
	Normal	0	56.9 ± 47.5
	group		
25	Control	0	139.5 \pm 50.0
	group		
	Present	1	109.9 ± 61.0
	invention	2	115.1 ± 59.0
		3	69.9 ± 64.3
30		4	67.2±70.6*

Mean ± Standard Deviation; Significantly different from Control group (*:p<0.05)

It is apparent from Table 2 that the compound of the present invention reduced the plasma TNF- lpha level in rats time-dependently.

2

35

15

5

10

Test Example 3 (Reduction of TNF- α content in skeletal muscle of rats)

The TNF- α content in skeletal muscle was determined by using Wistar fatty rats which are genetically obese, diabetic models, and a TNF- α inhibitory action of the compound of the present invention was evaluated.

Namely, hydrochloride of Compound No. 1 was administered to male Wistar fatty rats (16 week old), genetically obese, diabetic models in substantially the same manner as in Test Example 2. Ten rats were sacrificed before drug administration, and the first, second, third and fourth day after drug administration, respectively. Then, skeletal muscle was collected.

As the normal group, ten Wistar lean rats (16 week old) were sacrificed without drug administration and skeletal muscle was collected.

To the collected skeletal muscle, 0.1 M Tris-HCl buffer (pH 7.6) containing 1 M NaCl, 2 % (w/w) bovine serum albumin, 2 mM ethylenediaminetetraacetic acid disodium salt (EDTA), aprotinin (80 tripsin-inhibitory units/liter) and 0.02 % (w/w) NaN $_3$ was added in an amount of 20 weight times of the weight of the wet skeletal muscle. After ultrasonic disintegration, the mixture was centrifuged at 15000 rpm for 30 minutes to obtain a supernatant.

The amount of TNF- α in the obtained supernatant was determined in substantially the same manner as in Test Example 1.

The results are shown in Table 3. Table 3. TNF- α content in skeletal muscle (pg/g wet weight)

_		Days after drug	Amount of
_		administration	TNF- α (pg/g wet weight)
	Normal	0	156.7 ± 61.9
35 _	group		
	Control	0	356.6±105.6

20

5

10

15

25

30

10

15

20

25

30

35

<u>group</u>		
Present 1		200.1±165.1*
invention 2		181.4±108.2**
3	}	105.1± 96.4**
4	:	107.3± 95.7**

Mean \pm Standard Deviation; Significantly different from Control group (*:p<0.05, **:p<0.01)

It is apparent from Table 3 that the compound of the present invention reduced the TNF- α content in skeletal muscle of rats significantly and almost time-dependently.

Test Example 4 (Suppression of the active oxygen production in neutrophils)

The in vitro effect of the compound of the present invention on suppression of the active oxygen production in neutrophils was evaluated by determining the amount of peroxides in cells.

Namely, venous blood was collected from male Wistar rats (6 week old) while adding heparin. To the collected blood, the same volume of an aqueous solution of 3 %(w/w) dextran was added for separation of blood cells. After the mixture was allowed to stand for 30 minutes, precipitates obtained by centrifugation was suspended with saline. The suspension was piled on Ficoll-Hypaque solution (Sigma, USA), followed by centrifugation.

From the obtained precipitates, erythrocytes were removed by hemolysis to separate neutrophils.

The hemolysis was conducted in the following manner. Namely, 4 ml of an ice-cooled 0.2 %(w/w) aqueous solution of NaCl was added to the above precipitates, which was suspended quickly, followed by standing for 20 to 30 seconds to puncture the erythrocytes. Then, 4 ml of an ice-cooled 1.6 %(w/w) aqueous solution of NaCl was added to the obtained suspension, which was mixed to yield a mixed solution having the same osmotic pressure with the erythrocytes before puncture. The mixed solution was

10

15

20

centrifuged at 4 $^{\circ}$ C at 150 $^{\times}$ g for 5 minutes. After the supernatants were removed, the precipitates were washed with PBS (phosphate buffer saline).

The thus obtained erythrocytes were washed with saline, followed by addition of a minimum essential medium to prepare a neutrophils floating solution. The obtained neutrophils floating solution was fractionated into tubes so that the number of neutrophiles per tube is 106.

Then, hydrochloride of Compound No. 1 or Compound No. 8 was added to the obtained tubes at the concentration of 1 μ M. After incubation for one hour, a fluorescent pigment [DCFH-DA (2,7-dichlorofluoresceine diacetic acid)] was added, which was subjected to determination of the fluorescence intensity by FACScan (Becton Dickinton, USA).

As the control group, the fluorescence intensity in the case of adding no drug was determined.

The relative values of the fluorescence intensity in the drug addition group when the fluorescence intensity in the control group was 100 were calculated. These values were defined as the amount of peroxides caused by active oxygen derived from neutrophils.

The results are shown in Table 4.

Table 4. Fluorescence intensity and peroxide level

	Fluorescence	Peroxide
	intensity	<u>level</u>
Control group	707	100
Hydrochloride of	466	66
Compound No. 1		
(Present invention)		
Control group	377	100
Hydrochloride of	242	64
Compound No. 8		
(Present invention)		

It is apparent from Table 4 that the compound of the present invention suppressed the active oxygen production

35

in neutrophils.

5

10

15

20

25

TNF- α is produced by various cells such as monocytes, macrophages, neutrophils, fibroblasts, epithelial cells, astrocytes, and etc. TNF- α increases production of active oxygen in neutrophils, which are suggested to have a close relation with occurrence of rheumatoid arthritis [Clinical and Experimental Rheumatology, vol. 15, pp.233-237 (1997); Inflammation, vol. 20, pp.427-438 (1996)].

Therefore, it is considered that the compound of the present invention exhibited suppressive effects on the active oxygen production by reducing TNF- α production or TNF- α sensitivity in neutrophils based on the results of Test Example 4.

Industrial Applicability

The anti-inflammatory agent of the present invention is used as an agent for prophylaxis and treatment of TNF- α mediated inflammatory diseases such as diabetic complications (e.g., retinopathy, nephropathy, neutropathy, disorders in the great arteries, etc.), rheumatoid arthritis, osteoarthritis of the spine, osteoarthritis, low back pain, gout, postoperative or traumatic inflammation, remission of swelling, neuralgia, sore throat, cystitis, hepatitis, pneumonia, and etc.

CLAIMS

1. An anti-inflammatory agent which affects by way of a TNF- α inhibitory action and comprises a compound of the formula:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{2} = 0$$

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{2} = 0$$

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{2} = 0$$

10

15


20

25

5

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR³- where R³ represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R^1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R^1 ; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.

- 2. An anti-inflammatory agent according to Claim 1, wherein the heterocyclic group represented by R is a 5- to 7-membered monocyclic and heterocyclic group containing 1 to 4 hetero-atoms selected from oxygen, sulfur and nitrogen in addition to carbon as ring members or a condensed heterocyclic group.
- 3. An anti-inflammatory agent according to Claim 1, wherein R represents a heterocyclic group that may be substituted.
 - 4. An anti-inflammatory agent according to Claim 3, wherein the heterocyclic group is pyridyl, oxazolyl or thiazolyl.
- 35 5. An anti-inflammatory agent according to Claim 1, wherein the partial structural formula:



- 5 6. An anti-inflammatory agent according to Claim 1, wherein X represents CH.
 - 7. An anti-inflammatory agent according to Claim 1, wherein R^1 represents hydrogen.
 - 8. An anti-inflammatory agent according to Claim 1, wherein L and M respectively represent hydrogen.
 - 9. An anti-inflammatory agent according to Claim 1, wherein the compound is 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione.
 - 10. An anti-inflammatory agent according to Claim 1,
- wherein the compound is (R)-(+)-5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione.
- 11. Method for treating or preventing a TNF- α mediated inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound as defined in claim 1 or a pharmacologically acceptable salt thereof.
 - 12. Use of a compound as defined in claim 1 or a pharmacologically acceptable salt thereof for the
- 25 manufacture of an agent for prophylaxis or treatment of a TNF- α mediated inflammatory disease.

10

15

20

ABSTRACT

An anti-inflammatory agent which affects by way of a TNF- α inhibitory action and comprises a compound of the formula:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{0}$$

$$E \longrightarrow A - CH_{0} - CH_{0} = 0$$

$$Q \longrightarrow NH_{0}$$

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR³- where R³ represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R¹ represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R¹; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。	As a below named inventor, I hereby declare that:
私の住所、私書箱、国籍は下記の私の氏名の後に記載され た通りです。	My residence, post office address and citizenship are as stated next to my name.
下記の名称の発明に関して請求範囲に記載され、特許出類している発明内容について、私が最初かつ唯一の発明者(下記の氏名が一つの場合)もしくは最初かつ共同発明者であると(下記の名称が複数の場合)信じています。	I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Anti-inflammatory Agent
F.記発明の明細書(下記の欄でx目がついていない場合は、 本書に添付)は、	the specification of which is attached hereto unless the following box is checked:
□ _月_日に提出され、米国出願番号または特許協定条約 国際出願番号をとし、 (該当する場合) に訂正されました。	was filed on August 20, 1998 as United States Application Number or PCT International Application Number PCT/JP98/03092 and was amended on (if applicable).
私は、特許請求範囲を含む上記訂正後の明細書を検討し、 内容を理解していることをここに表明します。	I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.
私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。	I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Page 1 of 3

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks. Washington, DC 20231.

(modified) PTO/SB/106 (8-96) Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条 (b) 項に基き下記の、 米 国以外の国の少なくとも一ヵ国を指 定している特許協力条約 3 6 5 (a) 項に基ずく国際出願、又 は外国での特許出願もしくは発明者証の出願についての外国 優先権をここに主張するとともに、優先権を主張している。 本出願の前に出願された特許または発明者証の外国出願を以 下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出版

(Number) (番号)

(Country) (国名)

9-225302

Japan

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

> Priority Not Claimed 優先権主張なし

(Day/Month/Year Filed) (出願年月日) 21/08/1997

私は、第35編米国法典119条(e)項に基いて下記の米 国特許出願規定に記載された権利をここに主張いたします。

> (Application No.) (出類番号)

(Filing Date)

(出類日)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)

(Filing Date)

(出願番号)

(出願日)

私は、下記の米国法典第35損120条に基いて下記の米 国特許出層に記載された権利、 又は米国を指定している特許 協力条約365条(c)に基ずく権利をここに主張します。ま た、木出期の各請求範囲の内容が米国法典第35編112条 第1項又は特許協力条約で規定された方法で先行する米国特 許出額に開示されていない限り、その先行米国出願者提出日 以降で本出順者の日本国内または特許協力条約国際提出日ま での期間中に入手された、連邦規則法典第37編1条56項 で定義された特許資格の有無に関する重要な情報について開 示義務があることを認識しています。

> (Application No.) (出願番号)

(Filing Date) (出類日)

(Application No.) (出版番号)

(Filing Date) (出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

> (Status: Patented, Pending, Abandoned) (現況: 特許許可済、係属中、放棄済)

> (Status: Patented, Pending, Abandoned) (現況: 特許許可济、係属中、放棄済)

私は、私自身の知識に基すいて本宣言書中で私が行なう表 明が真実であり、かつ私の入手した情報と私の信じるところ に基ずく表明が全て真実であると信じていること、さらに故 意になされた虚偽の表明及びそれと同等の行為は米国法典第 18編第1()()1条に基ずき、罰金または拘禁、もしくはそ の両方により処罰されること、そしてそのような故意による 虚偽の声明を行なえば、出願した、又は既に許可された特許 の有効性が失われることを認識し、よってここに上記のごと く宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration

(日本語宣言書)

私は下記の発明者として、本出願に関する一切の ★手続きを米特許商標局に対して遂行する弁理上または代理人 、として、下記の者を指名いたします。(弁護士、または代理

日付

(第三以降の共同発明者についても同様に記載し、署名をす

200

第二共同発明者

第二共同発明者

ること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

人の氏名及び登録番号を明記のこと) Philippe Y. RIESEN (Reg. No. 35,657). Miriam SOHN (Reg. No. 35,368) Send Correspondence to: Philippe Y. Riesen 杏類送付先 Intellectual Property Department Takeda Chemical Industries, Ltd. 17-85, Jusohonmachi 2-chome Yodogawa-ku, Osaka 532-8686 Japan Direct Telephone Calls to: (name and telephone number) 直接電話連絡先: (名前及び電話番号) Philippe Y. Riesen (Phone) 81-6-6300-6124 (Japan) 81-6-6300-6601 (Fax) (E-mail) riesen_philippe@takeda.co.jp 唯一または第一発明者名 Full name of sole or first inventor <u>ODAKA Hiroyuki</u> 1-00 発明者の署名 日付 Inventor's signature Date (Lisyahr Old 住所 Residence HYOGO 651-1223 Japan 12-12, Katsuragi 2-chome, Kita-ku, Kobe-shi, Citizenship Japan 私書帶Takeda Chemical Industries (IPD) Post Office Address 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686 Japan

Full name of second joint inventor, if any

MOMOSE Yu

Residence

joint inventors.)

Second inventor's signature

2-00

Citizenship Japan 私書籍 Takeda Chemical Industries (IPD) Post Office Address 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686-Japan

8-7, Sumiregaoka 2-chome, Takarazuka-shi, HYOGO 665-0847 Japan

[] I attached sheet will follow

(Supply similar information and signature for third and subsequent

Date